Jennifer Kayden Lee - Mar 20, 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Signature
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Kayden Lee
Stock symbol
RYTM
Transactions as of
Mar 20, 2024
Transactions value $
-$707,005
Form type
4
Date filed
3/22/2024, 04:16 PM
Previous filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Sale -$350K -9.17K -36.55% $38.22 15.9K Mar 20, 2024 Direct F1, F2
transaction RYTM Common Stock Sale -$357K -9.07K -56.95% $39.33 6.85K Mar 20, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $37.75 to $38.68. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $38.75 to $39.72. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.